Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV‑2 Main Protease by Julia M. Flynn (16475720)

“…To understand resistance potential in M^pro, we performed comprehensive surveys of amino acid changes that can cause resistance to nirmatrelvir (Pfizer), and ensitrelvir (Xocova) in a yeast screen. …”

Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV‑2 Main Protease by Julia M. Flynn (16475720)

“…To understand resistance potential in M^pro, we performed comprehensive surveys of amino acid changes that can cause resistance to nirmatrelvir (Pfizer), and ensitrelvir (Xocova) in a yeast screen. …”

Moving Pieces in a Cellular Puzzle: A Cryptic Peptide from the Scorpion Toxin Ts14 Activates AKT and ERK Signaling and Decreases Cardiac Myocyte Contractility via Dephosphorylation... by Diana P. Goméz-Mendoza (9104908)

Moving Pieces in a Cellular Puzzle: A Cryptic Peptide from the Scorpion Toxin Ts14 Activates AKT and ERK Signaling and Decreases Cardiac Myocyte Contractility via Dephosphorylation... by Diana P. Goméz-Mendoza (9104908)

Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma by Hiroto Horiguchi (3215001)

“…The loss of Rhoh in Bcl-6^Tg mice led to a more rapid disease progression. Mechanistically, we demonstrated that deletion of Rhoh in these murine lymphoma cells was associated with decreased levels of the RhoH binding partner KAISO, a dual-specific Zinc finger transcription factor, de-repression of KAISO target Bcl-6, and downregulation of the BCL-6 target Blimp-1. …”

Treatment adoption and diffusion pattern. by Frédéric Galacteros (11105678)

“…In clinical studies, voxelotor has been shown to increase hemoglobin (Hb) and decrease hemolytic markers in patients with SCD. The objective of this study was to estimate the impact of voxelotor on the burden of SCD in France using a modeling approach, accounting for its anticipated adoption and diffusion over the next 5 years. …”

pH Dependence of Succinimide-Ester-Based Protein Cross-Linking for Structural Mass Spectrometry Applications by Esben Trabjerg (1540687)

“…The applicability of lysine-reactive cross-linking reagents to low-pH conditions remains unclear. Here, we cross-linked a mixture of eight model proteins at eight different pH conditions (pH 4.0–7.5) to investigate the pH dependency of DSS. …”

Image5_The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice.JPEG by Vladimir M. Pogorelov (133492)

“…Despite these benefits, the hallucinogenic actions of these drugs at the serotonin 2A receptor (5-HT2AR) limit their clinical use in diverse settings. …”

Engagement of monocytes, NK cells, and CD4⁺ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV_mac251 vaginal acquisition by Giacomo Gorini (5693312)

Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

“…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”

Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

“…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”

Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

“…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”

Tracking Daily Concentrations of PM_2.5 Chemical Composition in China since 2000 by Shigan Liu (11297966)

“…Here, we developed a full-coverage near-real-time PM_2.5 chemical composition data set at 10 km spatial resolution since 2000, combining the Weather Research and Forecasting–Community Multiscale Air Quality modeling system, ground observations, a machine learning algorithm, and multisource-fusion PM_2.5 data. …”

Comparison of SF-36 scores of participants with residual limb pain with a VAS score ≥5 and participants with a VAS score <5. by Martin C. Berli (9427264)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)